Glaucoma and the applications of carbonic anhydrase inhibitors

Sub-Cellular Biochemistry

Volumn 75, Issue , 2014, Pages 349-359

  Scozzafava, Andrea ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carbonic anhydrase; Carbonic anhydrase inhibitors; Dithiocarbamate; Glaucoma; Intraocular pressure; Sulfonamide; Vasodilation

Indexed keywords

ANIMALIA;

ACETAZOLAMIDE; BRINZOLAMIDE; CA4 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IV; CARBONATE DEHYDRATASE XII; NITRIC OXIDE; SULFANILAMIDE; SULFANILAMIDE DERIVATIVE; SULFONAMIDE; THIAZINE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ACETAZOLAMIDE; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASE IV; CARBONIC ANHYDRASES; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; NITRIC OXIDE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFANILAMIDES; SULFONAMIDES; THIAZINES;

EID: 84899775600     PISSN: 03060225     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-007-7359-2_17     Document Type: Article

References (44)

1. Quigley HA (2011) Glaucoma. Lancet 377:1367–1377
2. Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90:151–156
3. Mincione F, Menabuoni L, Supuran CT (2004) Clinical applications of the carbonic anhydrase inhibitors in ophthalmology. In: Supuran CT, Scozzafava A, Conway J (eds) Carbonic anhydrase – its inhibitors and activators. CRC Press, Boca Raton, pp 243–254
4. Mincione F, Scozzafava A, Supuran CT (2009) Antiglaucoma carbonic anhydrase inhibitors as ophthalomologic drugs. In: Supuran CT, Winum JY (eds) Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Wiley, Hoboken, pp 139–154
5. Carta F, Supuran CT, Scozzafava A (2012) Novel therapies for glaucoma: a patent review 2007–2011. Expert Opin Ther Pat 22:79–88
6. Friedenwald JS (1949) The formation of the intraocular fluid. Am J Ophthalmol 32:9–27
7. Kinsey VE (1953) Comparative chemistry of of aqueous humor in posterior and anterior chambers of rabbit eye. Arch Ophthalmol 50:401–417
8. Kinsey VE, Barany E (1949) The rate flow of aqueous humor. II. Derivation of rate of flow and its physiologic significance. Am J Ophthalmol 32:189–202
9. Wistrand PJ (1951) Carbonic anhydrase in the anterior uvea of the rabbit. Acta Physiol Scand 24:144–148
10. Becker B (1955) The mechanism of the fall in intraocular pressure by the carbonic anhydrase inhibitor Diamox. Am J Ophthalmol 39:177–183
11. Kinsey VE, Reddy DVN (1959) Turnover of total carbon dioxide in aqueous humors and the effect thereon of acetazolamide. Arch Ophthalmol 62:78–83
12. Supuran CT, Scozzafava A (2000) Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat 10:575–600
13. Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov 7:168–181
14. Supuran CT (2010) Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 20:3467–3474
15. Supuran CT (2010) Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets. Curr Pharm Des 16:3233–3245
16. Supuran CT, Scozzafava A, Casini A (2003) Carbonic anhydrase inhibitors. Med Res Rev 23:146–189
17. Maren TH (1967) Carbonic anhydrase: chemistry, physiology and inhibition. Physiol Rev 47:595–781
18. Miller WH, Dessert AM, Roblin RO Jr (1950) Heterocyclic sulfonamides as carbonic anhydrase inhibitors. J Am Chem Soc 72:4893–4896
19. Supuran CT, Scozzafava A, Casini A (2004) Development of sulfonamide carbonic anhydrase inhibitors (CAIs). In: Supuran CT, Scozzafava A, Conway J (eds) Carbonic anhydrase – its inhibitors and activators. CRC Press, Boca Raton, pp 67–147
20. Liao SY, Ivanov S, Ivanova A, Ghosh S, Cote MA, Keefe K, Coca-Prados M, Stanbridge EJ, Lerman MI (2003) Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CAXII) in glaucoma. J Med Genet 40:257–261
21. Maren TH, Jankowska L, Sanyal G, Edelhauser HF (1983) The transcorneal permeability of sulfonamide carbonic anhydrase innhibitors and their effect on aqueous humor secretion. Exp Eye Res 36:457–480
22. Sugrue MF (2000) Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Ret Eye Res 19:87–112
23. Maus TL, Larsson LI, McLaren JW, Brubaker RF (1997) Comparison of dorzolamide and acetazolamide as suppresors of aqueous humor flow in humans. Arch Ophthalmol 115:45–49
24. Silver LH (2000) Dose–response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide dose–response study group. Surv Ophthalmol 44(suppl 2):147–153
25. Aalto-Korte K (1998) Contact allergy to dorzolamide eyedrops. Contact Dermatitis 39:206
26. Carlsen J, Durcan J, Swartz M, Crandall A (1999) Nephrolithiasis with dorzolamide. Arch Ophthalmol 117:1087–1088
27. Thoe Schwartzenberg GW, Trop GE (1999) Anorexia, depression and dementia induced by dorzolamide eyedrops (Trusopt). Can J Ophthalmol 34:93–94
28. Konowal A, Morrison JC, Brown SV, Cooke DL, Maguire LJ, Verdier DV (1999) Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 127:403–406
29. Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT (1999) Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem 42:2641–2650
30. Scozzafava A, Briganti F, Mincione G, Menabuoni L, Mincione F, Supuran CT (1999) Carbonic anhydrase inhibitors. Synthesis of water-soluble, amino acyl/dipeptidyl sulfonamides possessing long lasting-intraocular pressure lowering properties via the topical route. J Med Chem 42:3690–3700
31. Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT (2000) Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action. J Med Chem 43:4542–4551
32. Scozzafava A, Menabuoni L, Mincione F, Supuran CT (2002) Carbonic anhydrase inhibitors. A general approach for the preparation of water soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long lasting, topical intraocular pressure lowering properties. J Med Chem 45:1466–1476
33. Alterio V, Di Fiore A, D’Ambrosio K, Supuran CT, De Simone G (2012) Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 112:4421–4468
34. Supuran CT (2011) Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 3:1165–1180
35. Supuran CT (2012) Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 27:759–772
36. Steele RM, Batugo MR, Benedini F, Biondi S, Borghi V, Carzaniga L, Impagnatiello F, Miglietta D, Chong WK, Rajapakse R, Cecchi A, Temperini C, Supuran CT (2009) Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorg Med Chem Lett 19:6565–6570
37. Mincione F, Benedini F, Biondi S, Cecchi A, Temperini C, Formicola G, Pacileo I, Scozzafava A, Masini E, Supuran CT (2011) Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett 21:3216–3221
38. Fabrizi F, Mincione F, Somma T, Scozzafava G, Galassi F, Masini E, Impagnatiello F, Supuran CT (2012) A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties.Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 27:138–147
39. Long DD, Frieman B, Hegde SS, Hill CM, Jiang L, Kintz S, Marquess DG, Purkey H, Shaw JP, Steinfeld T, Wilson MS, Wrench K (2013) A Multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma. Bioorg Med Chem Lett 23:939–943
40. Carta F, Aggarwal M, Maresca A, Scozzafava A, McKenna R, Supuran CT (2012) Dithiocarbamates: a new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations. Chem Commun (Cambridge) 48:1868–1870
41. Carta F, Aggarwal M, Maresca A, Scozzafava A, McKenna R, Masini E, Supuran CT (2012) Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. J Med Chem 55:1721–1730
42. Monti SM, Maresca A, Viparelli F, Carta F, De Simone G, Mühlschlegel FA, Scozzafava A, Supuran CT (2012) Dithiocarbamates strongly inhibit the beta-class fungal carbonic anhydrases from Cryptococcus neoformans, Candida albicans and Candida glabrata. Bioorg Med Chem Lett 22:859–862
43. Maresca A, Carta F, Vullo D, Supuran CT (2013) Dithiocarbamates strongly inhibit the betaclass carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 28:407–411
44. Temperini C, Scozzafava A, Supuran CT (2010) Carbonic anhydrase inhibitors. X-Ray crystal studies of the carbonic anhydrase II – trithiocarbonate adduct – an inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg Med Chem Lett 20:474–478